Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (NASDAQ: ILMN) is described by the company as a global leader in DNA sequencing and array-based technologies, serving research, clinical, and applied markets across genomics, multiomics, and proteomics. This news page aggregates recent press releases and announcements so readers can follow how Illumina’s technologies, collaborations, and financial disclosures evolve over time.
Company news highlights include product and platform launches, such as Illumina Connected Multiomics, a cloud-based software platform for analyzing and visualizing multiomic data, and Illumina Protein Prep, which the company states delivers broad coverage of the blood proteome and supports large-scale genomics studies. Illumina has also announced the Illumina Billion Cell Atlas, a large genome-wide genetic perturbation dataset developed through its BioInsight business to support AI-driven drug discovery in collaboration with pharmaceutical partners.
Investors can use this news feed to track Illumina’s preliminary financial results, earnings announcements, and capital markets activities, as reflected in press releases tied to quarterly and annual results and conference presentations. The page also captures updates on strategic agreements and acquisitions, including Illumina’s planned acquisition of Standard BioTools’ aptamer-based and functional proteomics business, as described in SEC filings and related communications.
In addition, Illumina’s news often covers leadership appointments, regulatory and market developments, and collaborations with genomics and population health partners such as MyOme. By reviewing these updates in one place, readers can better understand how Illumina positions its sequencing, multiomic, and proteomic offerings and how its corporate strategy and partnerships may influence its role in genomics and precision medicine. Bookmark this page to review new company-issued information as it becomes available.
Illumina Ventures, in partnership with Illumina (NASDAQ: ILMN), strengthens its European operations by adding four new team members. The new hires include Arnaud Autret as Head of European Operations, William Byrne as an Associate, and Venture Advisors Ronan Byrne and Ivan Coulter. This expansion aims to bolster their focus on genomics-focused projects across Europe, enhancing their support for startups in clinical diagnostics and life sciences. The firm, dedicated to investing in innovative healthcare solutions, continues to pursue growth and transformation in the healthcare landscape.
Illumina has announced the launch of DRAGEN v4.0, a state-of-the-art secondary analysis platform designed to enhance genomic analysis accuracy and efficiency. This platform expands capabilities in oncology, pharmacogenomics, and population genomics, allowing for improved insights into genetic diseases and drug response. Noteworthy features include enhanced PGx capabilities, boosted whole-genome sequencing, and new single-cell pipelines. Illumina's commitment to innovation in genomics positions it as a leader in the industry.
Illumina (NASDAQ: ILMN) has announced its inaugural Illumina Genomics Forum, scheduled for September 28 to October 1, 2022, in San Diego, featuring former President Barack Obama in a moderated discussion on healthcare equity and accessibility. The Forum aims to bring together global leaders to discuss advancements in genomic technology for personalized healthcare and its applications in cancer and infectious disease treatment. The event emphasizes the importance of making genomic health an inclusive standard of care.
GRAIL announces that the NHS-Galleri trial has completed enrollment of 140,000 volunteers in just over 10 months. This trial, the largest of its kind, aims to assess the Galleri multi-cancer early detection test alongside standard screening in England. Participants aged 50-77 were recruited from diverse backgrounds to evaluate the test's ability to identify asymptomatic cancers earlier than current methods. The study supports the NHS's goal to catch 75% of cancers at an early stage, potentially rolling out the test to an additional 1 million people.
Illumina, Inc. (NASDAQ:ILMN) will announce its second quarter 2022 financial results after market close on August 11, 2022. A conference call will be held at 2:00 PM PT to discuss these results, featuring CEO Francis deSouza and CFO Joydeep Goswami. Investors can join via Illumina's website or by dialing in. The replay will be available for 30 days post-event. Illumina focuses on advancing healthcare through genomic solutions, catering to life sciences, clinical, and applied markets.
Summary not available.
Mercy and GRAIL have announced a partnership to offer the innovative Galleri blood test for multi-cancer early detection (MCED). This test identifies early cancer signals for over 50 cancer types, including aggressive types like pancreatic and ovarian cancers. Recommended for individuals at higher risk, such as those aged 50+, the test aims to complement existing cancer screening methods. Although not covered by insurance, Mercy will assist qualifying patients with costs. The Galleri test could significantly enhance early cancer detection and treatment prospects.
Community Health Network has partnered with GRAIL to become the first healthcare system in central Indiana to offer the Galleri multi-cancer early detection blood test. This initiative targets individuals at elevated risk for cancer, particularly those over 50, enhancing existing cancer screening protocols. The Galleri test can detect signals from over 50 cancer types and accurately predicts their origin, potentially improving early detection rates and patient outcomes. This collaboration reflects a commitment to advancing patient care and addressing the public health challenge of late cancer detection.
Illumina (ILMN) announced its participation in Time Boost Capital I LP, a £30 million venture fund designed to support genomics startups graduating from Illumina Accelerator Cambridge. This investment aims to enhance breakthroughs in human health and includes commitments from LifeArc and Illumina Ventures. Since its launch in July 2020, the Accelerator has aided 13 startups, with over half founded by women. The fund will offer match funding for startups securing £500,000 to £4 million in new capital. Applications for the next funding cycle are due by October 1, 2022.
Illumina (NASDAQ: ILMN) has launched a research test in partnership with Merck to enhance cancer diagnostics through the TruSight™ Oncology 500 HRD assay. This test utilizes advanced genomic profiling to assess homologous recombination deficiency (HRD) in tumors, critical for understanding cancers like ovarian and breast. The assay enables labs to analyze over 500 genes, offering comprehensive insights with a single sample. It will be available globally, except in the US and Japan, starting August 2022. The collaboration aims to advance clinical research and expand access to cancer trials.